8-K: Keros Therapeutics Updates Investors on Clinical Programs and Pipeline

Keros Therapeutics provides an update on its clinical programs for elritercept, cibotercept, and KER-065, along with key milestones.

Summary

• Keros Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with disorders linked to dysfunctional TGFsuperfamily signaling.
• The company is developing product candidates designed to alter transforming growth factor-beta (TGF-) signaling and target pathways critical for the growth, repair, and maintenance of various tissue and organ systems.
• Elritercept (KER-050) is being investigated for the treatment of anemia and thrombocytopenia in patients with myelodysplastic syndromes (MDS) and myelofibrosis (MF).
• A Phase 2 clinical trial of elritercept in MDS showed robust responses in a broad range of patients, including those with high transfusion burden.
• In the MDS trial, 61.5% of patients had an ongoing transfusion independence response, and 42.3% had an ongoing response for over 52 weeks.
• Elritercept also demonstrated clinically meaningful and durable improvements in FACIT-Fatigue scores in transfusion-dependent patients.
• A Phase 3 registrational trial in MDS is planned, with positive feedback from the FDA on the design and endpoints.
• Elritercept is also being evaluated in a Phase 2 trial for MF, both as a monotherapy and in combination with ruxolitinib.
• Cibotercept (KER-012) is being developed for the treatment of pulmonary arterial hypertension (PAH) and cardiovascular disorders.
• Preclinical data for cibotercept showed reductions in pulmonary arterial pressure, right ventricle hypertrophy, and cardiac fibrosis in rodent PAH models.
• A Phase 2 clinical trial of cibotercept in PAH is ongoing.
• KER-065 is a novel activin receptor ligand trap for the treatment of obesity and neuromuscular disorders.
• Preclinical data suggests KER-065 has the potential to improve body composition by increasing muscle mass and decreasing fat mass, both as a monotherapy and in combination with GLP-1 receptor agonists.
• A Phase 1 clinical trial of KER-065 in healthy volunteers is underway, with data expected in Q1 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook on the company's clinical programs, with promising data and clear paths forward for its product candidates. The focus on addressing unmet needs and the potential for differentiated therapies contributes to a strong positive sentiment.

Positives

• Elritercept has shown promising results in Phase 2 trials for MDS, with a high percentage of patients achieving transfusion independence and improvements in fatigue.
• The planned Phase 3 trial for elritercept in MDS has received positive feedback from the FDA, indicating a clear path forward.
• Cibotercept has demonstrated positive preclinical results in PAH models, suggesting potential for treating pulmonary and cardiovascular disorders.
• KER-065 has shown potential to address both obesity and neuromuscular disorders by increasing muscle mass and decreasing fat mass.
• The company has a proprietary discovery approach that has generated a pipeline of potential product candidates.

Negatives

• The document mentions that some patients experienced treatment-related adverse events in the elritercept trials, including injection site reactions, dyspnea, and syncope.
• Fatal treatment emergent serious adverse events occurred in 3 patients in the elritercept MDS trial, although these were assessed as unrelated to the study treatment.
• Some patients in the elritercept MF trial experienced thrombocytopenia and diarrhea.
• The document notes that weight loss from GLP-1 RAs can lead to a loss of lean muscle mass, which KER-065 aims to address.

Risks

• The company has a limited operating history and has incurred historical losses.
• Keros' ability to raise additional funding to complete the development and commercialization of its product candidates is a risk.
• The company is dependent on the success of its product candidates, elritercept, cibotercept, and KER-065.
• There is a risk of delays in initiating, enrolling, or completing clinical trials.
• The company faces competition from third parties developing products for similar uses.
• Keros' ability to obtain, maintain, and protect its intellectual property is a risk.
• The company is dependent on third parties for manufacturing, clinical trials, and preclinical studies.

Future Outlook

Keros anticipates announcing additional data from its ongoing clinical trials for elritercept and cibotercept in Q4 2024 and data from the Phase 1 trial of KER-065 in Q1 2025. The company also plans to host an investor call in the second half of 2024 to provide additional details on the Phase 3 design for elritercept in MDS.

Industry Context

The document highlights the competitive landscape in the treatment of MDS, MF, PAH, and obesity, noting the limitations of current therapies and the potential for Keros' product candidates to address unmet needs. The mention of GLP-1 receptor agonists for obesity and their associated loss of lean muscle mass positions KER-065 as a potential complementary therapy.

Comparison to Industry Standards

• The document references Reblozyl (luspatercept) and RYTELOTM (imetelstat) as approved treatments for MDS, noting their limitations in terms of response rates and quality of life improvements, suggesting elritercept aims to provide a more effective solution.
• The document mentions a third-party Phase 3 clinical trial of sotatercept in PAH, highlighting the importance of the TGFsuperfamily in this disease and the challenges of dose-limiting side effects, suggesting cibotercept aims to provide a better safety profile.
• The document discusses the weight loss achieved with GLP-1 receptor agonists, but also notes the associated loss of lean muscle mass, positioning KER-065 as a potential solution to this issue.

Stakeholder Impact

• Shareholders may be positively impacted by the promising clinical data and the potential for future revenue generation.
• Patients with MDS, MF, PAH, obesity, and neuromuscular disorders may benefit from the development of new and effective therapies.
• Employees may be motivated by the company's progress and the potential to make a significant impact on patient lives.
• The company's success may lead to increased opportunities for suppliers and partners.

Next Steps

• Keros plans to announce additional data from Part 2 of the Phase 2 MDS trial for elritercept in Q4 2024.
• Keros plans to announce additional data from the Phase 2 MF trial for elritercept in Q4 2024.
• Keros plans to complete enrollment in the Phase 2 TROPOS Trial for cibotercept in Q4 2024.
• Keros plans to announce data from the Phase 1 healthy volunteer trial for KER-065 in Q1 2025.
• Keros plans to host an investor call in the second half of 2024 to provide additional details on the Phase 3 design for elritercept in MDS.

Key Dates

Keywords

elritercept, cibotercept, KER-065, myelodysplastic syndromes, myelofibrosis, pulmonary arterial hypertension, obesity, neuromuscular disorders, TGFsuperfamily, clinical trials, anemia, transfusion independence, muscle mass, fat mass